18:54 , Oct 27, 2017 |  BC Week In Review  |  Company News

Inivata and Levine Cancer Center form IKAN liquid biopsy network

Inivata Ltd. (Cambridge, U.K.) and the Levine Cancer Institute, part of the Carolinas HealthCare System (Charlotte, N.C.), formed the Inivata Knowledge Accumulation Network (IKAN). Inivata spokesperson Karen Chandler-Smith told BioCentury the network of cancer centers...
01:52 , Jul 15, 2017 |  BioCentury  |  Product Development

Excessive immunity?

Merck & Co. Inc. is mum on the cause of the deaths that led to a clinical hold on multiple myeloma trials combining Keytruda pembrolizumab with immunomodulatory agents, but overstimulation of the immune system is...
07:00 , Sep 26, 2016 |  BioCentury  |  Regulation

Digging into dosing

Clinical and preclinical data from Sarepta Therapeutics Inc. give hope that higher dosing of Exondys 51 eteplirsen could result in substantially higher dystrophin production than seen in its clinical trials. Figuring out how much and...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Out with the old

Data presented at the American Society of Clinical Oncology meeting in Chicago in previously treated multiple myeloma offer the tantalizing prospect that new regimens could move up to supplant Velcade bortezomib as standard of care...
01:44 , Jun 2, 2015 |  BC Extra  |  Clinical News

ASCO launches TAPUR trial

The American Society of Clinical Oncology launched the Targeted Agent and Profiling Utilization Registry (TAPUR) trial, a study of off-label uses of targeted therapies. TAPUR will collect real world clinical outcomes data on off-label use...